Should recombinant human growth hormone therapy be used in short small for gestational age children?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15269075.
- Also identified by PMC identifier 1720030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Short small for gestational age (SGA) children represent 20% of all children with short stature and therefore constitute a significant portion of the caseload in a growth clinic. The recent approval of recombinant human growth hormone (GH) for the treatment of short stature in SGA children by the European Union's Committee on Proprietary Medicinal Products offers a new licensed therapeutic option. This article examines the role of GH therapy in short SGA children with particular reference to selection of patients, effectiveness, safety, and its potential metabolic implications.
Medical subject headings
- Human Growth Hormone
- Infant, Small for Gestational Age